Dapagliflozin is an SGLT-2 Inhibitor that reduces blood sugar by increasing the excretion of sugar through the urine.

Genital and urinary infections is a potential risk with the use of SGLT2 Inhibitors like dapagliflozin.

Dapagliflozin has received FDA approval for use in heart failure (in patients even without diabetes).

Be aware of agents that may enhance the risk for hypoglycemia such an insulin and sulfonylureas.